Drug Trial Radar · NCT07776782
A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Jul 16, 2026
Primary completion
Nov 12, 2026
Study completion Nov 12, 2026
Sponsor
- Lead sponsor
- Mirador Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered with Concomitant Infliximab in Healthy Participants
Conditions
- Healthy Volunteer
Interventions
MT-201Drug
MT-201 and Infliximab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with non-SAEs and SAESTime frame: Up to 8 weeks post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mirador Clinical Department
San Diego, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.